Jan 31, 2024 5:15 pm EST Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties
Nov 9, 2023 7:18 am EST Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
Nov 4, 2023 12:15 pm EDT AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
Oct 16, 2023 7:00 am EDT Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
Oct 3, 2023 7:00 am EDT Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa
Sep 21, 2023 7:00 am EDT Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
Sep 18, 2023 7:00 am EDT Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
Sep 14, 2023 7:01 am EDT Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Sep 1, 2023 7:00 am EDT Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27